



## **Edelris Announces Research Services Agreement with Pfizer Inc. on Targeted Protein Degradation Modalities**

**Lyon (France) – September 3, 2024** - Edelris S.A.S., a leading Drug Discovery CRO, delivering novel small molecule leads against difficult-to-drug targets through a robust and high-throughput platform for Hit Generation and Optimization, today announced the signing of a multi-year research services agreement with Pfizer Inc. (NYSE: PFE).

The research will take place in Lyon at the heart of the biomedical and hospitals district, where Edelris operates state-of-the-art facilities for organic and medicinal chemistry, high-throughput purification, as well as high-density affinity screening. Under the terms of the agreement, Edelris will apply its cutting-edge affinity selection mass spectrometry (AS-MS) technologies and its unique Keytical Space™ of 2 million proprietary compounds against several of Pfizer's biological targets of interest.

In addition, Edelris and Pfizer will collaborate on a large-scale research endeavor to co-design, then synthesize in Edelris laboratories exclusive and focused compound libraries, with the ultimate aim, to better address unmet therapeutic needs. The ligands identified from these libraries may be further optimized by structure-enabled medicinal chemistry at Edelris as part of the collaboration or internalized by Pfizer.

Edelris will receive research support funding from Pfizer and be eligible for additional fees associated with Pfizer's election and designation of certain compounds from Edelris.

"Edelris is honored to collaborate with Pfizer in various discovery areas such as synthesis of sp<sup>3</sup>-enriched libraries, affinity screening, and medchem follow-up. Building upon the creativity, reliability, and agility of our teams and our engineered processes, within the vibrant French ecosystem, we are thrilled to uniquely contribute to this exciting new collaboration", said Nadège Laborde, Managing Director at Edelris.



“Edelris has pioneered dedicated expertise to build a best-in-class mass spectrometry-based screening platform, combining affinity selection technologies with an unrivalled compound collection,” said Jean-Yves Ortholand, co-founder and Chief Business & Strategy Officer at Edelris. “We are excited to dedicate expert resources and apply them to some of Pfizer’s highly challenging objectives.”

“This new collaboration with Edelris will allow us to create novel chemical equity and test millions of compounds against novel disease targets, hopefully resulting in new leads to pursue for hard-to-treat diseases with unmet need,” said Dr. Luca Mollo, Vice President and Medical Lead France at Pfizer. “We look forward to conducting this early discovery research with a company that has the advantage of being based in the heart of France’s robust biotechnology ecosystem and is equally dedicated to advancing science on behalf of patient communities in need of new treatment options.”

## About Edelris

Edelris, member of Janvier Group since 2024, is a leading Drug Discovery CRO, focusing on Hit identification and optimization and providing Compound Libraries, Organic & Medicinal Chemistry, High-Throughput Affinity Screening, and Analytical expert services to the Pharmaceutical, Cosmetic, Crop Protection, and Biotech industries.

Edelris brings to clients and partners innovative solutions and novel chemical matter to advance more efficiently their small molecules drug discovery programs. Operating from state-of-the-art laboratories located in Lyon, France, Edelris has been delivering scientific excellence and unmatched creativity to clients worldwide since 2005.

## About Janvier Group:

As an independent international player in the field of research, the Janvier Group is a reference player in terms of research models and preclinical services. Founded in 1960, the Janvier Group is one of the world leaders, recognized for the quality of its research models and associated services. Historically focused on research models, the Janvier Group is now an established player in preclinical services with its affiliates in France and internationally, offering a continuum of high value-added services from Drug Discovery to preclinical studies across a wide range of therapeutic areas. Today, with more than 600 employees, the Janvier Group operates throughout Europe and internationally with more than 3,500 public and private customers, to improve tomorrow’s health.

## Press contact

Nadège Laborde

Email: [nadege.laborde@edelris.com](mailto:nadege.laborde@edelris.com)